SCHEMBL6926009

SCHEMBL6926009

CCN1CCN(c2ccc(-c3nc(-c4cccc(Cl)c4)c[nH]3)cn2)CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.50
MGLL Q99685 1/20 0.44
DYRK3 O43781 1/20 0.42
CCNT1 O60563 1/20 0.42
CDK9 P50750 1/20 0.42
DYRK1A Q13627 1/20 0.42
DYRK2 Q92630 1/20 0.42
DYRK1B Q9Y463 1/20 0.42
ZAP70 P43403 1/20 0.42
PTPN11 Q06124 2/20 0.41
RET P07949 3/20 0.41
AURKA O14965 2/20 0.41
AURKB Q96GD4 2/20 0.41
SYK P43405 2/20 0.40
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40
KDR P35968 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6923696 0.89 RET (0.43) CNR2MGLLZAP70RETAURKA
SCHEMBL6924646 0.89 CNR2 (0.47) CNR2MGLLDYRK3CCNT1CDK9
SCHEMBL6924524 0.88 CNR2 (0.53) CNR2MGLLRET
SCHEMBL6925622 0.88 HRH3 (0.45) ZAP70RETAURKAAURKBSYK
SCHEMBL6928035 0.87 CNR2 (0.48) CNR2MGLLZAP70PTPN11RET
SCHEMBL6928322 0.87 CNR2 (0.46) CNR2MGLLDYRK3CCNT1CDK9
SCHEMBL6921614 0.87 CDK1 (0.43) CNR2DYRK3CCNT1CDK9DYRK1A
SCHEMBL6928854 0.87 MGLL (0.44) CNR2MGLLDYRK1AZAP70PTPN11
SCHEMBL6927424 0.85 MGLL (0.46) CNR2MGLLPTPN11KDM4EMAPT
SCHEMBL6926007 0.84 CNR2 (0.52) CNR2PTPN11RETKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010039277-A1 Compounds for the treatment of obesity ELLIOTT RICHARD L (US) 2001-11-08 US claimed
WO-2000066578-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY PFIZER PRODUCTS INC. (US) 2000-11-09 WO claimed
US-6514966-B2 Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine PFIZER INC. 2003-02-04 US disclosed
US-6355635-B1 IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY PFIZER INC. 2002-03-12 US disclosed
US-20010039277-A1 Compounds for the treatment of obesity ELLIOTT RICHARD L (US) 2001-11-08 US disclosed
WO-2000066578-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY PFIZER PRODUCTS INC. (US) 2000-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039277-A1 Compounds for the treatment of obesity NPY1R, NPY4R, NPY2R CNR2 122/4885MGLL 234/4885DYRK3 1244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.